Innovus Pharma Expands Its Men's And Women's Health Franchise With The Addition Of Exclusive Rights To Androvit To Support Overall Male Prostate And Sexual Health And Urocis XR For Urinary Tract Infection (UTI) For Women From Q Pharma Spain
SAN DIEGO, CA, Oct 27, 2015 (Marketwired via COMTEX) -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (otcqb:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and vitality, announced today that it entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize AndroVit(R), a proprietary supplement to support overall prostate and male sexual health, and Urocis(R) XR, a proprietary 24 hours extended release of Vaccinium Marcocarpon for urinary tract infection.
Urocis(R) XR is a proprietary extended release of Vaccinium Marcocarpon (cranberry) shown to provide 24 hour coverage in the body to increase compliance of the use of the product to get full benefit. The product is a high seller for Q Pharma in Europe due to its efficacy.
According to Business Insights in their "The Antibacterials Market Outlook to 2016" report, Urinary tract infections are very common, with an estimated incidence of 9.6% in the 7 million people in the US. Urinary tract infections typically affect post-pubescent females and the elderly.
AndroVit(R) is a proprietary supplement to support overall prostate and male sexual health currently marketed in Europe. AndroVit(R) was specifically formulated with ingredients known to support the normal prostate health and vitality and male sexual health.
"The two products are an excellent fit and complementation to our current pipeline and increase our offerings to our clients in these large markets," said Dr. Damaj, President & CEO of Innovus Pharma. "We are excited to partner with Innovus Pharma on the commercialization of three products," said Cesar Quintanilla, President & Chief Executive Officer of Q Pharma. "We look forward to a successful launch of AndroVit(R) and Urocis(R) XR in the US in the near future." Continued Mr. Quintanilla.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare(TM) OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com/test/
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority and to successfully commercialize such products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Contact:
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com
858.964-5123
SOURCE: Innovus Pharmaceuticals Inc.
Help employers find you! Check out all the jobs and post your resume.
Urocis(R) XR is a proprietary extended release of Vaccinium Marcocarpon (cranberry) shown to provide 24 hour coverage in the body to increase compliance of the use of the product to get full benefit. The product is a high seller for Q Pharma in Europe due to its efficacy.
According to Business Insights in their "The Antibacterials Market Outlook to 2016" report, Urinary tract infections are very common, with an estimated incidence of 9.6% in the 7 million people in the US. Urinary tract infections typically affect post-pubescent females and the elderly.
AndroVit(R) is a proprietary supplement to support overall prostate and male sexual health currently marketed in Europe. AndroVit(R) was specifically formulated with ingredients known to support the normal prostate health and vitality and male sexual health.
"The two products are an excellent fit and complementation to our current pipeline and increase our offerings to our clients in these large markets," said Dr. Damaj, President & CEO of Innovus Pharma. "We are excited to partner with Innovus Pharma on the commercialization of three products," said Cesar Quintanilla, President & Chief Executive Officer of Q Pharma. "We look forward to a successful launch of AndroVit(R) and Urocis(R) XR in the US in the near future." Continued Mr. Quintanilla.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare(TM) OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com/test/
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority and to successfully commercialize such products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Contact:
Reuven Rubinson
Vice President of Finance
rreubinson@innovuspharma.com
858.964-5123
SOURCE: Innovus Pharmaceuticals Inc.
Help employers find you! Check out all the jobs and post your resume.